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The hMSH2 gene is a major component of the mismatch repair
(MMR) system in the human. Germline mutations of this gene
account for about one-third of hereditary non-polyposis colorectal
cancer (HNPCC) cases and is somatically mutated in 3% of
sporadic colorectal tumours (Liu et al, 1996). Recently, the pres-
ence of a polymorphic T®C transition in the splicing donor of
exon 13 of hMSH2 has been associated with an increased suscepti-
bility to develop colorectal cancer (CRC) (Brentnall et al, 1995;
Goessl et al, 1997). While these observations have been made in
sporadic tumours, the frequency of the variant sequence in familial
CRC remains unknown.
It has been suggested that the substitution could affect exon 13
splicing (Fishel et al, 1993; Brentnall et al, 1995). If this was the
case an association with the microsatellite mutator phenotype
(MMP) characteristic of tumours with an altered MMR system
(Aaltonen et al, 1993; Ionov et al, 1993) could be expected. The
aims of this study were to analyse: (a) whether the intron splice
acceptor variant sequence is associated to a major susceptibility to
develop sporadic or familial CRC in the Spanish population; and
(b) whether it affects the splicing of the exon 13 of hMSH2 gene
and associates with the MMP.
MATERIALS AND METHODS
Patients
Group 1: Spanish CRC patients
Between July 1991 and July 1993, 166 consecutive CRC patients
of the Hospital de Sant Pau (Barcelona, Spain) were prospectively
included in a study designed to evaluate the prognostic value of
genetic alterations in CRC (Tórtola et al, 1999). Validated family
history was obtained by personal interview with at least one
member of the family using a standardized protocol. Fifteen (9%)
of the 166 patients were excluded because of inadequate follow-
up. In two cases (1.2%) analysis of hMSH2 was not possible due
to polymerase chain reaction (PCR) failure. The remaining 149
cases were included in the present study. Incidence of intron splice
acceptor variant sequence were compared to a control group of 75
healthy adult blood donors coming from the same region as the
CRC patients. While age and sex were known, no cancer family
history was available.
Group 2: Individuals with family history of CRC
Seventy-seven individuals (38 with CRC and the remaining 39 at
risk) from the Catalonian Hereditary Colorectal Cancer Registry
were also studied. Individuals have been classified to belong to
HNPCC families (seven families) when they meet the Amsterdam
criteria; or HNPCC-like families (20 families) when they meet less
stringent criteria described elsewhere (Hall et al, 1994).
hMSH2 analyses
Germline hMSH2 substitution
Normal colonic tissue (Group 1) or peripheral blood lymphocytes
(PBL) (Group 2 and controls) served as a source of constitutional
tissue for the detection of germline hMSH2 substitution. A 370-bp
region of the hMSH2 gene including exon 13 and intronic splice-
site flanking regions, was amplified essentially as described
(Fishel et al, 1993). Identity of the amplified fragment was
confirmed by cycle sequencing. The presence of the substitution
was analysed by single strand conformation polymorphism
(SSCP) analysis and confirmed by sequencing analysis. All results
were confirmed at least twice.
Analysis of hMSH2 alternative splicing
The presence of an alternative splicing in the hMSH2 gene has
been previously evidenced in PBL and other tissues of healthy
donors (Xia et al, 1996). In order to study whether the variant
sequence affected the splicing of exon 13 in PBL and normal
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available were analysed. PBL of 22 members of group 2 (18
normal/four variant) and 42 normal colorectal mucosae obtained
from patients of group 1 (22 normal/20 variant) were studied.
Total RNA extraction and cDNA generation were performed
following standard procedures. A 689-bp fragment of the hMSH2
gene, including exons 12, 13, 14 and 15 was amplified using
primers MSH7up: 5¢-TCACGTGTCAAATGGAGCC-3¢ and
MSH8dw: 5¢-GCTTAGGGAAATTAGCAAGC-3¢. To test the
efficiency of reverse transcription (RT) reaction, p53 cDNA was
also amplified. Whenever, in addition to the expected 689 bp PCR
product, a 484-bp band was amplified it was interpreted as the
presence of an alternative transcript lacking exon 13. Identity of
the amplified fragments was confirmed by cycle sequencing.
Microsatellite instability analysis
In a first approach, five microsatellite sequences were amplified
and analysed on sequencing gels (Tórtola et al, 1999). Cases
displaying mobility shifts in two or more microsatellites were
considered positive for MMP+. K-ras and p53 gene status has been
also analysed in the present series and has been the subject of a
separate report (Tórtola et al, 1999). Details of all experimental
procedures described above are available upon request.
Statistical analysis
All values are expressed as mean ± standard deviation (s.d.).
Contingency tables were analysed by two-sided Fisher’s exact or
c2 test. The odds ratio (OR) was calculated to estimate the associ-
ation. Meta-analysis of available studies was performed using a
random or fixed-effects model after testing for heterogeneity with
Cochran Q test. Overall survival distributions were calculated by
the Kaplan–Meier method and analysed using the log-rank test.
RESULTS
A total of 149 patients with CRC and 75 healthy controls were
analysed for the intronic germline T®C transition upstream of
exon 13 of hMSH2. Thirty-four of the 149 (23%) CRC patients
were heterozygous (T/C) for the T®C transition. It should be
mentioned that no subjects homozygous for the transition have
been identified indicating that alleles are not in Hardy–Weinberg
equilibrium. The incidence of variant sequences was significantly
higher when compared to healthy donors (eight out of 75; 11%; 
P < 0.027; OR: 2.48, 95% confidence interval (CI) 1.08–5.66]. In
neither group were homozygous variant sequences observed. It is
of note that variant sequence analyses of normal mucosa and
corresponding tumour yielded a perfect match in a small series of
CRC tumours analysed (ten variant/ten normal).
The presence of the germline substitution was correlated with
clinicopathological and genetic variables. Variant sequences were
more frequently detected in left-sided tumours (P < 0.02) and in
the more advanced stages of the disease (P < 0.03) (Table 1).
Interestingly, no increase in variant sequences was observed in
younger patients. The presence of the germline substitution did not
influence overall survival as assessed by the log-rank test. It is
noteworthy that no correlation was observed between microsatel-
lite instability and the variant sequence. Finally, no correlation
with K-ras or p53 mutations was observed (Table 1).
Initially, it was suggested that prevalence of this substitution
could be higher in familial colorectal cancer (Fishel et al, 1993).
Validated cancer family history was available in 110 of the 149
CRC cases. Twelve of them belonged to HNPCC or HNPCC-like
families. Only two of them (17%) showed the germline substitu-
tion. In this small series no differences between sporadic and
familial CRC regarding variant sequences were observed. To
further study this issue 38 familial CRC patients referred to the
Catalonian Hereditary Colorectal Cancer Registry were also
analysed. Again, seven of them (18%) harboured the variant
sequence, a percentage that parallels that of the sporadic CRC
cases. In contrast only four of 39 (10%) of the relatives at risk
harboured the substitution. The variant sequence is not restricted
to CRC cases in these families; moreover in some of them the
polymorphism has been exclusively detected in at risk individuals.
In this setting, as some of the patients may be related, the rele-
vance of data obtained with familial CRC is only descriptive
without any statistical validation.
Transcripts lacking exon 13 were detected in 20 of the 22 (91%)
PBL analysed, an incidence similar to what has been reported (Xia
et al, 1996), therefore validating our technique. In contrast, none
of the 42 normal colorectal mucosae contained the alternative tran-
scripts. The presence or absence of the variant sequence did not
influence the appearance of alternative splicing.
DISCUSSION
In this study we have shown that the incidence of the intronic
germline substitution in Spanish sporadic CRC patients is higher
than in the control population. These results concur with those
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Table 1 Features of sporadic colorectal cancer regarding the presence of germline intron splice acceptor
site sequence in exon 13 of the hMSH2 gene
Splice acceptor site genotype Normal/variant Normal/normal P
n = 34 n = 115
Clinical-pathological characteristics
Age at diagnosis (years) 67 (33–86) 67 (52–89) NS
Location (right/left) 4/30 37/78 <0.02
Dukes’ (A–B/C–D) 12/22 65/50 <0.03
Overall survival 47% 65% NS
Genetic alterations
K-ras (+/–) 15/17 46/66 NS
p53 (+/–) 15/17 56/56 NS
MMP (+/–) 0/32 8/104 NSreported by Goessl et al (1997) but are at odds with those of Hall et
al (1994b), all of them dealing with sporadic CRC. The limited
number of analysed cases in all studies have led us to perform a
meta-analysis that has evidenced that the presence of the variant
sequence increased CRC risk (P < 0.002; OR: 1.91; 95% CI
1.28–2.86; heterogeneity: 0.071). A meta-analysis with a random
effects model, which is more conservative because accounts for
heterogeneity, was also done and the overall association was still
significant (P = 0.038). However, caution should be kept about this
increased risk since we cannot rule out that other negative results
may have not been reported.
Although the variant sequence has been described in patients
belonging to HNPCC families (Fishel et al, 1993; Hall et al, 1994),
the prevalence of the polymorphism in these patients was
unknown. In our series the prevalence of the substitution in
familial CRC patients parallels that of sporadic CRC. Interestingly,
there was no apparent increase of the prevalence of the variant
sequence in at risk members of these families when compared to
the control group.
Right-sided tumours are characteristic of HNPCC. In agreement
with the lack of correlation between the substitution and familial
CRC, in our series left-sided tumours display a higher incidence of
the variant sequence. In contrast with previous reports (Goessl et
al, 1997), the incidence of the polymorphism is higher in the more
advanced stages of the disease. However, overall survival was not
affected by the substitution indicating that this aberration should
not be considered a marker of bad prognosis.
Since the variant sequence could be a genetic risk factor for
CRC, its possible effect in the structure and function of hMSH2
gene was investigated. First, it was ruled out that the substitution
affected the alternative splicing of hMSH2 mRNA. Although the
alternative splicing was observed in the majority of PBL (Xia et al,
1996, and the present study) none of the normal colonic mucosae
harboured it independently of variant status. Second, no associa-
tion was observed with the MMP. While this association has been
previously analysed in few cases (Goessl et al, 1997), we have
clearly shown that there is no correlation between microsatellite
instability and the variant hMSH2 sequence.
To summarize, our observations strongly suggest that the variant
sequence of hMSH2 is a genetic risk factor for CRC in the Spanish
population. This increased susceptibility does not associate with
the microsatellite mutator phenotype (MMP). Further larger
studies are needed to confirm that the intron splice site
polymorphism in the hMSH2 confers susceptibility to colorectal
cancer.
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